Voyager Therapeutics (VYGR) Retained Earnings (2014 - 2026)
Voyager Therapeutics (VYGR) posted Retained Earnings of -$263000.0 for Q1 2026, up 99.94% sequentially from -$445.9 million in Q4 2025, and down 32.16% YoY from -$387681.5 in Q1 2025.
Voyager Therapeutics (VYGR) Retained Earnings (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Retained Earnings for 13 years, with the latest figure at -$263000.0 in Q1 2026.
- Quarterly Retained Earnings fell 32.16% year-over-year to -$263000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$263000.0 (down 32.16% YoY) and the FY2025 annual result came in at -$445.9 million, down 171.2% from the prior year.
- Retained Earnings advanced to -$263000.0 in Q1 2026 per VYGR's latest filing, from -$445.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $634.7 million in Q2 2025 and troughed at -$445.9 million in Q4 2025.
- A 5-year average of $2.0 million and a median of -$263000.0 in 2026 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 328152.9% in 2022, then sank 1268018.18% in 2025.
- Over 5 years, Retained Earnings stood at $452.7 million in 2022, then slumped by 157.69% to -$261.2 million in 2023, then jumped by 339.79% to $626.3 million in 2024, then tumbled by 171.2% to -$445.9 million in 2025, then surged by 99.94% to -$263000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$263000.0, -$445.9 million, and -$418.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 4.38 Bn |
| 10 | Voyager Therapeutics | 204.71 Mn | 88.37 Mn | - | 653.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 653.05 Mn |
| Mar 31, 2026 | -263,000.00 |
| Dec 31, 2025 | -445.91 Mn |
| Sep 30, 2025 | -418.48 Mn |
| Jun 30, 2025 | 634.70 Mn |
| Mar 31, 2025 | -199,000.00 |
| Dec 31, 2024 | 626.30 Mn |
| Sep 30, 2024 | -33,000.00 |
| Jun 30, 2024 | -282.70 Mn |
| Mar 31, 2024 | -506,000.00 |
| Dec 31, 2023 | -261.18 Mn |
| Sep 30, 2023 | -248,000.00 |
| Jun 30, 2023 | -133,000.00 |
| Mar 31, 2023 | 486.52 Mn |
| Dec 31, 2022 | 452.71 Mn |
| Sep 30, 2022 | -337,000.00 |
| Jun 30, 2022 | -387.50 Mn |
| Mar 31, 2022 | -368.42 Mn |
| Dec 31, 2021 | -138,000.00 |
| Sep 30, 2021 | 440.33 Mn |